Methyltransferase inhibitors for treatment of COVID19

Project Information

MeTIC

Grant agreement ID: 101069369

DOI 10.3030/101069369

Project closed

EC signature date 25 May 2022

Start date 1 June 2022

End date 30 November 2023

Funded under

• European Research Council (ERC)

Total cost € 0,00

EU contribution € 150 000,00

Coordinated by

TECHNISCHE UNIVERSITAET MUENCHEN
Germany

Objective

Our IP secured drug DZNep is effective in treating SARS-CoV-2 infections in preclinical disease models and uniquely suppresses virus growth, triggers the innate immunity and facilitates tissue regeneration. The ERC-PoC will enable the transition from preclinical to clinical research.

Fields of science

• natural sciences › biological sciences › microbiology › virology
• medical and health sciences › health sciences › infectious diseases › RNA viruses › coronaviruses

Keywords

• MeTIC

Programme(s)

• HORIZON.1.1 - European Research Council (ERC) Main Programme

Topic(s)

• ERC-2022-POC1 - ERC PROOF OF CONCEPT GRANTS1

Call for proposal

ERC-2022-POC1

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Host institution

TECHNISCHE UNIVERSITAET MUENCHEN

• Net EU contribution: € 150 000,00
• Address: Arcisstrasse 21 ; 80333 Muenchen ; Germany
• Region: Bayern › Oberbayern › München, Kreisfreie Stadt
• Activity type: Higher or Secondary Education Establishments
• Total cost: No data

Beneficiaries (1)

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

• Net EU contribution: € 150 000,00
• Address: Arcisstrasse 21 ; 80333 Muenchen
• Region: Bayern › Oberbayern › München, Kreisfreie Stadt
• Activity type: Higher or Secondary Education Establishments
• Total cost: No data